MedTrace Logo

Continuous Positive Airway Pressure (CPAP) Treatment in Coronary Artery Disease and Sleep Apnea

NCT00519597 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 511

Last updated 2018-11-15

No results posted yet for this study

Summary

Obstructive sleep apnea (OSA) worsens the prognosis in patients with coronary artery disease (CAD). Many of these subjects do not report daytime sleepiness, and therefore, are not considered for OSA treatment with continuous positive airway pressure (CPAP). There is lack of evidence regarding the impact of CPAP on the long-term prognosis of CAD patients with OSA. The Randomized Intervention with CPAP in CAD and OSA (RICCADSA) trial is designed to address if CPAP treatment reduces the combined rate of new revascularization, myocardial infarction, stroke and cardiovascular mortality over mean follow-up period of 3-years in CAD patients with OSA without daytime sleepiness.Secondary outcomes include cardiovascular biomarkers, cardiac function, maximal exercise capacity and quality of life at baseline, 3-month- and 1-year follow-up as well as polysomnographic findings and adherence to CPAP therapy.

Conditions

Interventions

DEVICE

ResMed S8 (Auto-CPAP)

AutoCPAP during sleep

Sponsors & Collaborators

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Swedish Heart Lung Foundation

    collaborator OTHER

  • Heart Foundation of Karnsjukhuset Sweden

    collaborator UNKNOWN

  • ResMed Foundation

    collaborator OTHER

  • Skaraborg Hospital

    lead OTHER_GOV

Principal Investigators

  • Yüksel Peker, Ass. Prof. · Göteborg University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2013-03-31
Completion
2013-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00519597 on ClinicalTrials.gov